{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T01:19:38Z","timestamp":1782436778461,"version":"3.54.5"},"reference-count":37,"publisher":"Public Library of Science (PLoS)","issue":"10","license":[{"start":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T00:00:00Z","timestamp":1698278400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>Tuberculosis stands as a prominent cause of mortality in developing countries. The treatment of tuberculosis involves a complex procedure requiring the administration of a panel of at least four antimicrobial drugs for the duration of six months. The occurrence of treatment failure after the completion of a standard treatment course presents a serious medical problem. The purpose of this study was to evaluate antimicrobial drug resistant features of <jats:italic>Mycobacterium tuberculosis<\/jats:italic> associated with treatment failure. Additionally, it aimed to evaluate the effectiveness of second line drugs such as amikacin, linezolid, moxifloxacin, and the efflux pump inhibitor verapamil against <jats:italic>M<\/jats:italic>. <jats:italic>tuberculosis<\/jats:italic> isolates associated with treatment failure. We monitored 1200 tuberculosis patients who visited TB centres in Lahore and found that 64 of them were not cured after six months of treatment. Among the <jats:italic>M<\/jats:italic>. <jats:italic>tuberculosis<\/jats:italic> isolates recovered from the sputum of these 64 patients, 46 (71.9%) isolates were simultaneously resistant to rifampicin and isoniazid (MDR), and 30 (46.9%) isolates were resistant to pyrazinamide, Resistance to amikacin was detected in 17 (26,5%) isolates whereas resistance to moxifloxacin and linezolid was detected in 1 (1.5%) and 2 (3.1%) isolates respectively. Among MDR isolates, the additional resistance to pyrazinamide, amikacin, and linezolid was detected in 15(23.4%), 4(2.6%) and 1(1.56%) isolates respectively. One isolate simultaneously resistant to rifampicin, isoniazid, amikacin, pyrazinamide, and linezolid was also identified. In our investigations, the most frequently mutated amino acid in the treatment failure group was Serine 315 in <jats:italic>katG<\/jats:italic>. Three novel mutations were detected at codons 99, 149 and 154 in <jats:italic>pncA<\/jats:italic> which were associated with pyrazinamide resistance. The effect of verapamil on the minimum inhibitory concentration of isoniazid and rifampicin was observed in drug susceptible isolates but not in drug resistant isolates. Rifampicin and isoniazid enhanced the transcription of the efflux pump gene r<jats:italic>v1258<\/jats:italic> in drug susceptible isolates collected from the treatment failure patients. Our findings emphasize a high prevalence of MDR isolates linked primarily to drug exposure. Moreover, the use of amikacin as a second line drug may not be the most suitable choice in such cases.<\/jats:p>","DOI":"10.1371\/journal.pone.0293194","type":"journal-article","created":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T17:36:15Z","timestamp":1698341775000},"page":"e0293194","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":7,"title":["Antimicrobial drug resistant features of Mycobacterium tuberculosis associated with treatment failure"],"prefix":"10.1371","volume":"18","author":[{"given":"Fizza","family":"Mushtaq","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed Mohsin","family":"Raza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adeel","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hina","family":"Aslam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atiqa","family":"Adeel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sidrah","family":"Saleem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2648-1952","authenticated-orcid":true,"given":"Irfan","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2023,10,26]]},"reference":[{"issue":"4","key":"pone.0293194.ref001","doi-asserted-by":"crossref","first-page":"653","DOI":"10.3201\/eid1804.110888","article-title":"Characterization of Mycobacterium orygis as M. tuberculosis complex subspecies","volume":"18","author":"J van Ingen","year":"2012","journal-title":"Emerging infectious diseases"},{"issue":"1","key":"pone.0293194.ref002","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1007\/s13205-016-0423-9","article-title":"Emergence of mixed infection of Beijing\/Non-Beijing strains among multi-drug resistant Mycobacterium tuberculosis in Pakistan","volume":"6","author":"S Mustafa","year":"2016","journal-title":"3 Biotech"},{"issue":"10311","key":"pone.0293194.ref003","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1016\/S0140-6736(21)01546-4","article-title":"Global, regional, and national mortality among young people aged 10\u201324 years, 1950\u20132019: a systematic analysis for the Global Burden of Disease Study 2019","volume":"398","year":"2021","journal-title":"Lancet"},{"key":"pone.0293194.ref004","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ijid.2016.10.026","article-title":"Classifying new anti-tuberculosis drugs: rationale and future perspectives","volume":"56","author":"S Tiberi","year":"2017","journal-title":"International Journal of Infectious Diseases"},{"issue":"3","key":"pone.0293194.ref005","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.ijmyco.2014.06.004","article-title":"Mutation pattern in rifampicin resistance determining region of rpoB gene in multidrug-resistant Mycobacterium tuberculosis isolates from Pakistan","volume":"3","author":"O Qazi","year":"2014","journal-title":"International journal of mycobacteriology"},{"issue":"11","key":"pone.0293194.ref006","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1016\/j.jiac.2021.06.020","article-title":"Profiling and identification of novel rpoB mutations in rifampicin-resistant Mycobacterium tuberculosis clinical isolates from Pakistan","volume":"27","author":"M Qadir","year":"2021","journal-title":"J Infect Chemother"},{"key":"pone.0293194.ref007","doi-asserted-by":"crossref","first-page":"4119","DOI":"10.2147\/IDR.S333433","article-title":"rpoB Mutations and Effects on Rifampin Resistance in Mycobacterium tuberculosis","volume":"14","author":"MC Li","year":"2021","journal-title":"Infect Drug Resist"},{"key":"pone.0293194.ref008","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.meegid.2016.09.004","article-title":"Overview on mechanisms of isoniazid action and resistance in Mycobacterium tuberculosis","volume":"45","author":"AN Unissa","year":"2016","journal-title":"Infection, Genetics and Evolution"},{"issue":"5","key":"pone.0293194.ref009","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1093\/jac\/dkg446","article-title":"Mode of action of pyrazinamide: disruption of Mycobacterium tuberculosis membrane transport and energetics by pyrazinoic acid","volume":"52","author":"Y Zhang","year":"2003","journal-title":"Journal of Antimicrobial Chemotherapy"},{"issue":"1","key":"pone.0293194.ref010","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/1471-2180-14-165","article-title":"Molecular characterization of amikacin, kanamycin and capreomycin resistance in M\/XDR-TB strains isolated in Thailand","volume":"14","author":"A Sowajassatakul","year":"2014","journal-title":"BMC microbiology"},{"key":"pone.0293194.ref011","article-title":"Definitions and reporting framework for tuberculosis\u2013 2013 revision. Geneva","author":"WH Organization","year":"2020"},{"issue":"1","key":"pone.0293194.ref012","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.tim.2021.05.001","article-title":"Efflux pumps in Mycobacterium tuberculosis and their inhibition to tackle antimicrobial resistance","volume":"30","author":"M Laws","year":"2022","journal-title":"Trends in Microbiology"},{"issue":"1","key":"pone.0293194.ref013","doi-asserted-by":"crossref","first-page":"3970","DOI":"10.1038\/s41467-020-17735-y","article-title":"Efflux pump activity potentiates the evolution of antibiotic resistance across S. aureus isolates","volume":"11","author":"A Papkou","year":"2020","journal-title":"Nature Communications"},{"key":"pone.0293194.ref014","first-page":"9","article-title":"Insights on Mycobacterium leprae Efflux Pumps and Their Implications in Drug Resistance and Virulence.","author":"D Machado","year":"2018","journal-title":"Frontiers in Microbiology"},{"key":"pone.0293194.ref015","article-title":"Critical discussion on drug efflux in Mycobacterium tuberculosis","author":"S Remm","year":"2021","journal-title":"FEMS Microbiol Rev"},{"issue":"9","key":"pone.0293194.ref016","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1128\/JCM.00549-17","article-title":"Development of a One-Step Multiplex PCR Assay for Differential Detection of Major Mycobacterium Species","volume":"55","author":"H Chae","year":"2017","journal-title":"J Clin Microbiol"},{"key":"pone.0293194.ref017","first-page":"108401","article-title":"Evaluation of MGIT 960 System for the Second-Line Drugs Susceptibility Testing of Mycobacterium tuberculosis","volume":"2013","author":"H Kim","year":"2013","journal-title":"Tuberculosis Research and Treatment"},{"issue":"3","key":"pone.0293194.ref018","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1128\/JCM.44.3.688-692.2006","article-title":"Multicenter laboratory validation of the BACTEC MGIT 960 technique for testing susceptibilities of Mycobacterium tuberculosis to classical second-line drugs and newer antimicrobials","volume":"44","author":"S R\u00fcsch-Gerdes","year":"2006","journal-title":"J Clin Microbiol"},{"issue":"15","key":"pone.0293194.ref019","doi-asserted-by":"crossref","first-page":"2714","DOI":"10.1002\/elps.1150181505","article-title":"SWISS-MODEL and the Swiss-Pdb Viewer: An environment for comparative protein modeling","volume":"18","author":"N Guex","year":"1997","journal-title":"ELECTROPHORESIS"},{"key":"pone.0293194.ref020","article-title":"Biomolecular simulation: the GROMOS96 manual and user guide.","author":"WFv Gunsteren","year":"1996","journal-title":"Z\u00fcrich; Groningen; Z\u00fcrich: Biomos; Vdf, Hochschulverlag AG an der ETH Z\u00fcrich"},{"issue":"13","key":"pone.0293194.ref021","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1002\/jcc.20084","article-title":"UCSF Chimera\u2014A visualization system for exploratory research and analysis","volume":"25","author":"EF Pettersen","year":"2004","journal-title":"Journal of Computational Chemistry"},{"issue":"4","key":"pone.0293194.ref022","doi-asserted-by":"crossref","first-page":"e265","DOI":"10.1016\/S2666-5247(21)00301-3","article-title":"The 2021 WHO catalogue of Mycobacterium tuberculosis complex mutations associated with drug resistance: A genotypic analysis","volume":"3","author":"TM Walker","year":"2022","journal-title":"Lancet Microbe"},{"issue":"4","key":"pone.0293194.ref023","first-page":"356","article-title":"Study on the prevalence of Beijing genotype Mycobacterium tuberculosis and its relationship with second-line anti-tuberculosis drug resistance","volume":"43","author":"C Liang","year":"2020","journal-title":"Zhonghua Jie He He Hu Xi Za Zhi."},{"issue":"8","key":"pone.0293194.ref024","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1089\/mdr.2019.0215","article-title":"Second Line Injectable Drug Resistance and Associated Genetic Mutations in Newly Diagnosed Cases of Multidrug-Resistant Tuberculosis","volume":"26","author":"V Ramakrishna","year":"2020","journal-title":"Microb Drug Resist"},{"key":"pone.0293194.ref025","doi-asserted-by":"crossref","first-page":"216","DOI":"10.3389\/fmicb.2019.00216","article-title":"Mutations in Efflux Pump Rv1258c (Tap) Cause Resistance to Pyrazinamide, Isoniazid, and Streptomycin in M. tuberculosis","volume":"10","author":"J Liu","year":"2019","journal-title":"Front Microbiol"},{"issue":"10","key":"pone.0293194.ref026","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1093\/infdis\/jiy710","article-title":"Diverse Clinical Isolates of Mycobacterium tuberculosis Develop Macrophage-Induced Rifampin Tolerance","volume":"219","author":"KN Adams","year":"2019","journal-title":"J Infect Dis"},{"issue":"Pt 10","key":"pone.0293194.ref027","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1099\/mic.0.066787-0","article-title":"Salmonella enterica serovar Typhimurium BaeSR two-component system positively regulates sodA in response to ciprofloxacin","volume":"159","author":"P Guerrero","year":"2013","journal-title":"Microbiology (Reading)."},{"key":"pone.0293194.ref028","doi-asserted-by":"crossref","first-page":"533","DOI":"10.2217\/fmb-2019-0002","article-title":"Roles of two-component regulatory systems in antibiotic resistance","volume":"14","author":"AR Tierney","year":"2019","journal-title":"Future Microbiol"},{"issue":"2","key":"pone.0293194.ref029","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/j.1365-2958.2010.07110.x","article-title":"A lipoprotein modulates activity of the MtrAB two-component system to provide intrinsic multidrug resistance, cytokinetic control and cell wall homeostasis in Mycobacterium","volume":"76","author":"HT Nguyen","year":"2010","journal-title":"Mol Microbiol"},{"issue":"6","key":"pone.0293194.ref030","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1111\/joim.12004","article-title":"Biofilm infections, their resilience to therapy and innovative treatment strategies","volume":"272","author":"U R\u00f6mling","year":"2012","journal-title":"J Intern Med"},{"issue":"5","key":"pone.0293194.ref031","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1084\/jem.20030846","article-title":"Transcriptional Adaptation of Mycobacterium tuberculosis within Macrophages: Insights into the Phagosomal Environment","volume":"198","author":"D Schnappinger","year":"2003","journal-title":"J Exp Med"},{"issue":"5","key":"pone.0293194.ref032","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.chom.2007.09.006","article-title":"Mycobacterium tuberculosis invasion of macrophages: linking bacterial gene expression to environmental cues","volume":"2","author":"KH Rohde","year":"2007","journal-title":"Cell Host Microbe"},{"issue":"2","key":"pone.0293194.ref033","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1128\/CMR.19.2.382-402.2006","article-title":"Clinically relevant chromosomally encoded multidrug resistance efflux pumps in bacteria","volume":"19","author":"LJ Piddock","year":"2006","journal-title":"Clin Microbiol Rev"},{"issue":"1","key":"pone.0293194.ref034","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1128\/AAC.01462-13","article-title":"Efflux inhibition with verapamil potentiates bedaquiline in Mycobacterium tuberculosis","volume":"58","author":"S Gupta","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"pone.0293194.ref035","doi-asserted-by":"crossref","first-page":"185","DOI":"10.2217\/fmb-2018-0277","article-title":"Modulatory effects of verapamil in rifampicin activity against Mycobacterium tuberculosis","volume":"14","author":"KR Caleffi-Ferracioli","year":"2019","journal-title":"Future Microbiol"},{"issue":"3","key":"pone.0293194.ref036","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02530-18","article-title":"High Prevalence of Bedaquiline Resistance in Treatment-Naive Tuberculosis Patients and Verapamil Effectiveness","volume":"63","author":"H Ghajavand","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"pone.0293194.ref037","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02107-17","article-title":"Verapamil Targets Membrane Energetics in Mycobacterium tuberculosis","volume":"62","author":"C Chen","year":"2018","journal-title":"Antimicrob Agents Chemother"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0293194","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T17:36:38Z","timestamp":1698341798000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0293194"}},"subtitle":[],"editor":[{"given":"Atul","family":"Vashist","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2023,10,26]]},"references-count":37,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2023,10,26]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0293194","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,26]]}}}